Check out Tatva Chintan Pharma IPO GMP aka IPO Grey Market Premium, Kostak rates, and Subject to Sauda rates as of today. Tatva Chintan Pharma IPO GMP is going good around 1000-1100 level.
Tatva Chintan Pharma IPO to hit the market on 16 July 2021 AND closes on 20 July 2021 The company to raise ā¹450 crore via initial public offer, ā¹225 crore via fresh issue and ā¹225 crore stake sale of their existing share holder. They are one of the largest manufacturer of SDAs for zeolites in India, based in Gujarat. The financial looks good and we can expect it to zoom in the grey market. The price band is fixed at ā¹1073 to ā¹1083 per equity share. The Tatva Chintan Pharma IPO to list on NSE and BSE.
What is Tatva Chintan Pharma IPO GMP Today?
-
The Tatva Chintan Pharma IPO GMP aka grey market premium is ā¹1100.
What is Tatva Chintan Pharma IPO Kostak Rates Today?
-
The Tatva Chintan Pharma IPO kostak rate is ā¹350.
What is Tatva Chintan Pharma IPO Subject to Sauda Price Today?
-
The Tatva Chintan Pharma IPO subject to sauda rates is ā¹10500.
Tatva Chintan Pharma IPO Expected Returns?
-
The Tatva Chintan Pharma expected return is 100%.
Tatva Chintan Pharma IPO GMP Rates day by day with Kotak rates.
| Date |
GMP |
Kostak | Subject to |
| 29 July | ā¹1150 | ā¹350 | ā¹10500 |
| 28 July | ā¹1150 | ā¹350 | ā¹10500 |
| 27 July | ā¹1100 | ā¹350 | ā¹10500 |
| 26 July | ā¹1050 | ā¹300 | ā¹10000 |
| 26 July | ā¹1050 | ā¹300 | ā¹10000 |
| 25 July | ā¹1000 | ā¹400 | ā¹8000 |
| 24 July | ā¹1000 | ā¹400 | ā¹8000 |
| 23 July | ā¹1000 | ā¹400 | ā¹8000 |
| 22 July | ā¹900 | ā¹300 | ā¹8000 |
| 21 July | ā¹870 | ā¹450 | ā¹7500 |
| 20 July | ā¹750 | ā¹450 | ā¹7500 |
| 19 July | ā¹750 | ā¹450 | ā¹7500 |
| 18 July | ā¹750 | ā¹450 | ā¹7500 |
| 17 July | ā¹750 | ā¹450 | ā¹7500 |
| 16 July | ā¹690 | ā¹350 | ā¹7000 |
| 15 July | ā¹650 | ā¹300 | ā¹6000 |
| 14 July | ā¹570 | ā¹400 | ā¹5000 |
| 13 July | ā¹480 | ā¹350 | ā¹5000 |
| 12 July | ā¹570 | ā¹350 | ā¹5000 |
| 11 July | ā¹450 | ā¹350 | ā¹5000 |
| 10 July | ā¹450 | ā¹350 | ā¹5000 |
| 09 July | ā¹450 | ā¹350 | ā¹5000 |
| 08 July | ā¹0 | ā¹0 | ā¹0 |
| 07 July | ā¹0 | ā¹0 | ā¹0 |
About Tatva Chintan Pharma
Our Company is promoted by Chintan Shah, Ajay Patel and Shekhar Somani, who each have over 24 years in the specialty chemicals manufacturing industry and have established strong business relationships with domestic as well as overseas customers. In addition, we are led by a well ā qualified and experienced management team, which we believe has demonstrated its ability to manage and grow our operations and has substantial experience in the sectors in which we operate. We believe that the knowledge and experience of our management team provides us with a significant competitive advantage as we seek to grow our business.
Tatva Chintan Pharma IPO Date & Price Band
| IPO Open: | 16 July 2021 |
| IPO Close: | 20 July 2021 |
| IPO Size: | Approx ā¹450 Crores |
| Fresh Issue: | Approx ā¹225 Crores |
| Offer for Sale: | Approx ā¹225 Crores |
| Face Value: | ā¹10 Per Equity Share |
| Price Band: | ā¹1073 to ā¹1083 Per Share |
| Listing on: | BSE & NSE |
| Retail Portion: | 35% |
| Equity: | – Shares |
| Discount: | N/A |
Tatva Chintan Pharma IPO Market Lot
| Minimum Lot Size: | Minimum 13 Shares |
| Minimum Amount: | ā¹14,079 |
| Maximum Lot Size: | Maximum 182 Shares |
| Maximum Amount: | ā¹197,106 |
Tatva Chintan Pharma IPO Allotment & Listing
| Basis of Allotment: | 26 July 2021 |
| Refunds: | 27 July 2021 |
| Credit to Demat Account: | 28 July 2021 |
| Listing Date: | 29 July 2021 |
Tatva Chintan Pharma IPO GMP aka Grey Market Premium FAQs:
- IPO Grey Market Premium (Tatva Chintan Pharma IPO GMP) mention is valid for the specific date as mentioned in the header.
- We are not buying and selling IPO forms on IPO Grey Market.
- Kostak Rate is the premium one gets by selling his/her IPO application (in an off-market transaction) to someone else even before allotment or listing of the issue.
- Do not subscribe for IPO by just seeing premium Price as it may change anytime before listing. Subscribe only considering Fundamental of the companies.




